Literature DB >> 11594581

Molecular genetics of cutaneous lymphomas.

S Whittaker1.   

Abstract

The underlying molecular basis of primary cutaneous lymphomas has not yet been clarified. However, abnormalities of cell cycle control genes and well-defined tumor suppressor genes such as p53 are common and may contribute to disease progression and treatment resistance. Biallelic inactivation of tumor suppressor genes usually occurs by a combination of deletion, point mutation, and/or promotor hypermethylation. The detection of UVB-specific mutations of p53 requires confirmation but may have important implications for the management of patients with mycosis fungoides. Molecular cytogenetic studies have identified common regions of chromosomal deletion and amplification, which suggests the presence and location of genes that are of critical importance in the pathogenesis of cutaneous lymphoma.

Entities:  

Mesh:

Year:  2001        PMID: 11594581     DOI: 10.1111/j.1749-6632.2001.tb03709.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  3 in total

Review 1.  Immunopathogenesis and therapy of cutaneous T cell lymphoma.

Authors:  Ellen J Kim; Stephen Hess; Stephen K Richardson; Sara Newton; Louise C Showe; Bernice M Benoit; Ravi Ubriani; Carmela C Vittorio; Jacqueline M Junkins-Hopkins; Maria Wysocka; Alain H Rook
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

2.  Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides.

Authors:  Laura Y McGirt; Peilin Jia; Devin A Baerenwald; Robert J Duszynski; Kimberly B Dahlman; John A Zic; Jeffrey P Zwerner; Donald Hucks; Utpal Dave; Zhongming Zhao; Christine M Eischen
Journal:  Blood       Date:  2015-06-16       Impact factor: 22.113

3.  TP53 Gene Status Affects Survival in Advanced Mycosis Fungoides.

Authors:  Gitte Wooler; Linea Melchior; Elisabeth Ralfkiaer; Lise Mette Rahbek Gjerdrum; Robert Gniadecki
Journal:  Front Med (Lausanne)       Date:  2016-11-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.